#1 Clinical Trials Search in Europe

Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

↓

Matched clinical trials

  • Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

    Recruiting

    3 1 1
    Investigated Drugs:
    France Germany Greece Italy The Netherlands Poland +1

  • Continuation study of JDQ443 in patients with KRAS G12C‑mutated non‑small cell lung cancer receiving JDQ443 as monotherapy or drug combination

    Recruiting

    1 1 1 1
    Investigated Drugs:
    Belgium Denmark France Italy Spain

  • Phase 1/2 Study of CR-001 Safety and Dose Finding in Adults with Locally Advanced or Metastatic Solid Tumors

    Recruiting

    2 1 1
    France Ireland Italy Romania Spain

  • Zongertinib with cisplatin or carboplatin and pemetrexed, with or without pembrolizumab, for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Germany Spain

  • Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Belgium Bulgaria Czechia Finland France +10

  • Testing the Safety and Effects of TUB-030 in Patients with Advanced Head and Neck Cancer or Non-Small-Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Romania Spain

  • Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Estonia France Germany Ireland Italy +1

  • Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Belgium France Germany Hungary Italy +3

  • A study to evaluate the safety and effectiveness of rilvegostomig, ramucirumab, and a drug combination in adults with advanced or metastatic non-small cell lung cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Italy Spain

  • A Study of Telisotuzumab Adizutecan Compared to Standard Treatment in Adults with Advanced Non-Small Cell Lung Cancer After Previous Treatment

    Recruiting

    4 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Belgium France Germany Italy The Netherlands +3